Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

GlobeNewswire EN Nachrichten

GlobeNewswire verbreitet Pressemeldungen und Pflichtmitteilungen von börsennotierten Gesellschaften. Der Großteil der Mitteilungen stammt von Unternehmen aus Nordamerika, Großbritannien und den nordeuropäischen Ländern.
 
16.03.26 - 02:42
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China (GlobeNewswire EN)
 
BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China and the second globally....
16.03.26 - 00:12
Perseus Announces Sale of Interest in Meyas Sand Project (GlobeNewswire EN)
 
Perth, Western Australia, March 16, 2026 (GLOBE NEWSWIRE) -- PERSEUS ANNOUNCES SALE OF GROUP INTEREST IN MEYAS SAND PROJECT IN SUDAN...
15.03.26 - 22:30
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate (GlobeNewswire EN)
 
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients....
14.03.26 - 19:33
HII′S Ingalls Shipbuilding Celebrates Apprentice School Graduates (GlobeNewswire EN)
 
PASCAGOULA, Miss., March 14, 2026 (GLOBE NEWSWIRE) -- HII's (NYSE: HII) Ingalls Shipbuilding division celebrated 70 apprentice school graduates during a ceremony at the shipyard today. The event honored the newest class to complete the Department of Labor-registered program, which combines classroom instruction, paid on-the-job training and industry-recognized credentials....
14.03.26 - 17:03
Iceland Seafood International hf: Annual General Meeting 24 March 2026 - Final proposals and agenda (GlobeNewswire EN)
 
The Annual General Meeting of Iceland Seafood International hf will be held on Tuesday 24 March 2026 at 4pm at Hilton Reykjavík Nordica, Suðurlandsbraut 2, 108 Reykjavik, Iceland.  The meeting will be in Icelandic....
14.03.26 - 15:18
First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear (GlobeNewswire EN)
 
New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes...
14.03.26 - 15:03
Sharpen Your Knives: It′s the Final Round of Northern California′s Battle of the Blades (GlobeNewswire EN)
 
We started with 72 competing chefs 6 months ago, and now we're down to the final 3. Join us for an awe-inspiring cooking contest to select Sysco NorCal's CULINARY ARTIST OF THE YEAR!...
14.03.26 - 09:33
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 (GlobeNewswire EN)
 
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (“ATTD”) in Barcelona on March 14, 2026 highlighting positive 52-week follow-up results from the Company's Phase II COVALENT-111 study evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 2 diabetes (“T2D”)....
14.03.26 - 01:33
Digital Asset Technologies Announces Settlement Agreement with Former Auditor (GlobeNewswire EN)
 
- NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES -...
14.03.26 - 00:09
Nobel Announces Change of Transfer Agent (GlobeNewswire EN)
 
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- Nobel Resources Corp. (TSX–V: NBLC; OTCPK: NBTRF) (the “Company” or “Nobel”) announces the appointment of Odyssey Trust Company (“Odyssey”) as the Company's registrar and transfer agent. Odyssey will now be responsible for all transfers of Nobel's shares through their office in Toronto rather than Computershare Investor Services Inc., which has resigned at the Company's request. Shareholders need not take action in respect of the change in transfer agent....
14.03.26 - 00:03
South Bow Files 2025 Annual Disclosure Documents (GlobeNewswire EN)
 
CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) -- South Bow Corp. (TSX & NYSE: SOBO) (South Bow) filed its 2025 annual disclosure documents on March 13, 2026....
13.03.26 - 23:57
Domestic Metals Completes Surface IP Geophysical Survey at Smart Creek and Announces Amendment to Warrant Terms of Unit Private Placement (GlobeNewswire EN)
 
Domestic Metals Completes Surface IP Geophysical Survey at Smart Creek and Announces Amendment to Warrant Terms of Unit Private Placement...
13.03.26 - 23:30
Silvercrest Asset Management (SAMG) to Announce Fourth Quarter and Year-End 2025 Results and Host Investor Conference Call (GlobeNewswire EN)
 
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) announced today it will host a teleconference at 8:30 am Eastern Time on March 17, 2026, to discuss the company's financial results for the fourth quarter and year ended December 31, 2025. A news release containing the results will be issued before the open of the U.S. equity markets and will be available on http://ir.silvercrestgroup.com/....
13.03.26 - 22:42
Star Equity Holdings to Release Fourth Quarter 2025 Financial Results on March 17  (GlobeNewswire EN)
 
OLD GREENWICH, Conn., March 13, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) ("Star" or the "Company"), formerly Hudson Global, Inc. (Nasdaq: HSON and HSONP), a diversified holding company, announced today that it will release its financial results for the fourth quarter ended December 31, 2025, after the close of the market on Tuesday, March 17, 2026....
13.03.26 - 22:33
Publication relating to transparency notification (GlobeNewswire EN)
 
REGULATED INFORMATION...
13.03.26 - 22:18
Home BancShares, Inc. Announces First Quarter Earnings Release Date and Conference Call (GlobeNewswire EN)
 
CONWAY, Ark., March 13, 2026 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced it expects to release First Quarter 2026 earnings after the market closes on April 15, 2026. Following this release, management will conduct a conference call to review these earnings at 1:00 p.m. CT (2:00 p.m. ET) on Thursday, April 16, 2026....
13.03.26 - 22:09
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire EN)
 
ZUG, Switzerland, March 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a member of the executive committee of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended....
13.03.26 - 22:03
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire EN)
 
JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”)....
13.03.26 - 22:03
Peyto Exploration & Development Corp. Confirms Monthly Dividend for April 15, 2026 (GlobeNewswire EN)
 
CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) -- Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto") confirms that the monthly dividend with respect to March 2026 of $0.11 per common share is to be paid on April 15, 2026, for shareholders of record on March 31, 2026....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Heldenhaftigkeit ist eine Todesart, keine Lebensart. - Gabriel Laub
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!